Health & Fitness
Health and Fitness
Health and Fitness
Thu, January 29, 2009
Wed, January 28, 2009 Vitro Receives Notice of Allowance for Adult Stem Cell Patent from the United States Patent and Trademark Office
GOLDEN, Colo.--([ BUSINESS WIRE ])--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced notification from the United States Patent Office (USPTO) indicating the successful examination of its patent application entitled, "Generation and Differentiation of Adult Stem Cells." (App No 11/256,673) The USPTO issued an Official Notice of Allowance indicating the allowance of certain claims and the impending issuance of a new United States patent.
Dr. Jim Musick, Vitro's President and CEO said, "We are pleased to announce Notice of Allowance for our adult stem cell patent from the USPTO. Our proprietary cell line generation technology now includes adult stem cells with commercial application to diabetes drug discovery and development and eventual cellular therapy. We believe that our technology will yield commercial products of value in treating diabetes and other debilitating diseases. Our new patent may also result in licensing opportunities for Vitro as well. Our work is focused on adult stem cells that may have properties comparable to embryonic stem cells. The recent FDA approval of human clinical trials of embryonic stem cells for spinal cord injury is an important advance in determining the effectiveness of stem cell therapy in the treatment of previously untreatable human disease. We expect that our technology will lead to advances in understanding the role of adult cells and other non-embryonic cells and their derivatives in regenerative medicine."
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG)([ http://www.vitrodiag.com ]) is committed to "Harnessing the Power of Cells" and owns proprietary technology, cell lines and related products with potential application to treatment of cancer, diabetes and infertility. Vitro recently established a new, high tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. The current focus is development and commercialization of adult stem cell products for use in diabetes research, drug development and therapy. In addition and as recently announced, Vitro's stem cell technology also has application to cancer stem cell research for development of targeted cell therapies for malignancies including those of the pancreas, lung and brain.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.
